A 4‐site, single‐visit intradermal postexposure prophylaxis regimen for previously vaccinated patients: experiences with >5000 patients.
We previously demonstrated that 4&#x2010;site, intradermal, single&#x2010;visit rabies booster vaccination provides immunogenicity greater than that provided by the standard 2&#x2010;booster, 2&#x2010;visit regimen. The regimen has been routinely used in 5116 patients since 1998 without any treatment failure. It is not only effective but also saves vaccine costs and transportation expenses and improves compliance.